AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 07:38:25 2024-04-19 am EDT 5-day change 1st Jan Change
10,843 GBX -0.65% Intraday chart for AstraZeneca PLC -2.13% +2.15%
This Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
AstraZeneca: presents new data at ECCMID CF
The market is pinning its hopes on earnings reports Our Logo
ASTRAZENECA : Receives a Buy rating from JP Morgan ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean... Our Logo
Market sentiment sours Our Logo
ASTRAZENECA : Deutsche Bank returns to 'Hold CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial CI
ASTRAZENECA : Deutsche Bank drops its Sell rating ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca Our Logo
RBC raises Admiral; Barclays cuts Phoenix Group AN
AstraZeneca: improvements in biliary tract cancer CF
AstraZeneca's hails Imfinzi survival data on cancer form AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial MT
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors CI
AstraZeneca: expects a sharp rise in kidney disease CF
ASTRAZENECA : Barclays reiterates its Buy rating ZD
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices MT
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... Our Logo
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts RE
Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector MT
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study MT
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval DJ
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
136 USD
Average target price
162 USD
Spread / Average Target
+19.09%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca: The market’s harsh reaction to the Q4 miss seems unreasonable